INDAPTUS THERAPEUTICS (INDP)

[midastouch017]

Intec Pharma Expands Intellectual Property for AP-CDLD with Patent in South Korea

JERUSALEM, Israel, April 6, 2016 /PRNewswire/ --

Intec Pharma Ltd. (NTEC) (INTP.TA), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the company has been informed that the Korean Intellectual Property Office granted a South Korean patent to the company's patent application for an Accordion Pill containing certain drugs, including the combination Carbidopa and Levodopa. The patent, granted under No. 10-1601649, is titled "Carbidopa / Levodopa Gastroretentive Drug Delivery," and is currently scheduled to remain in force until April 17, 2029. The patent belongs to the company's IN-7 patent family, which pertains to the combination of certain drugs with the Accordion Pill.

Zeev Weiss, CEO of Intec Pharma, said: "The approval of this new South Korean patent is an important step for our company in extending the intellectual property protection, and potential future market, for our leading product candidate, the Accordion Pill Carbidopa/Levodopa, beyond the U.S., South Africa and Israel."